HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 7-12

  Elledge, Richard M ^a   Green, Stephanie ^b   Ciocca, Daniel ^c   Pugh, Reginald ^d   Allred, D Craig ^a   Clark, Gary M ^a   Hill, Julian ^e   Ravdin, Peter ^a   O'Sullivan, Janet ^b   Martino, Silvana ^f   Osborne, C Kent ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c Laboratorio de Reproduccion y Lactancia Mendoza   (Argentina)

^d ALLEGHENY HEALTH NETWORK   (United States)

^e N Mississippi Hematol and Oncology   (United States)

^f The Breast Center Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; ONCOPROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; DRUG RESPONSE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DETERMINATION; TREATMENT FAILURE;

ADULT; AGED; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN;

EID: 0031930148     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., Eudey, L., and McGuire, W. L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10: 599-605, 1992.
2. Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C-M., Golouh, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M., Burki, K., Catiglione, M., Collins, J., Lindtner, J., and Senn, H-J. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1056, 1992.
3. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res. Treat., 24: 85-95, 1992.
4. Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., Ryden, S., and Sigurdsson, H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett., 8: 137-144, 1994.
5. Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R. C., Farndon, J., Cairns, J., Harris, A. L., and Home, C. H. Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65: 118-121, 1992.
6. Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., and De Placido, S. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early breast cancer without axillary lymph node metastases. J. Clin. Oncol., 14: 2702-2708, 1996.
7. Archer, S. G., Eliopoulous, A., Spandidos, D., Barnes, D., Ellis, I. O., Blamey, R. W., Nicholson, R. I., and Robertson, J. F. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer, 72: 1259-1266, 1995.
8. Ciocca, D. R., Fujimura, F. K., Tandon, A. K., Clark, G. M., Mark, C., Lee-Chen, G. J., Pounds, G. W., Vendely, P., Owens, M. A., Pandian, M. R., and McGuire, W. L. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J. Natl. Cancer Inst. (Bethesda), 84: 1279-1282, 1992.
9. Elledge, R. M., Green, S., Howes, L., Clark, G. M., Berardo, M., Allred, D. C., Ciocca, D., Osborne, C. K., Ravdin, P., O'Sullivan, J., and Langone, G. bc1-2, p53, and response to tamoxifen in ER-positive metastatic breast cancer: A Southwest Oncology Group Study. J. Clin. Oncol., 15: 1916-1922, 1997.
10. Ravdin, P. M., Green, S., Dorr, T. M., McGuire, W. L., Fabian, C., Pugh, R. P., Carter, R. D., Rivkin, S. E., Borst, J. R., and Belt, R. J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group Study. J. Clin. Oncol., 10: 1284-1291, 1992.
11. Press, M. F., Hung, G., Godolphin W., Slamon, D. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res., 54: 2771-2777, 1994.
12. Niehans, G. A., Singleton, T. P., Dykoski, D., and Kiang, D. T. Stability of HER-2/neu expression over time and at multiple metastatic sites. J. Natl. Cancer Inst. (Bethesda), 85: 1230-1235, 1993.
13. DiGiovanna, M. P., Carter, D., Flynn, S. D., and Stern, D. F. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2neu-overexpressing invasive human breast tumours. Br. J. Cancer, 74: 802-806, 1996.
14. Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X., and Slamon, D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10: 2435-2445, 1995.
15. Berns, M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., and Klijn, J. G. M. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene, 159: 11-18, 1995.
16. Leitzel, K., Teramoto, Y., Konrad, K., Chinchilli, V. M., Volas, G., Grossberg, H., Harvey, H., Demers, L., and Lipton, A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol., 13: 1129-1135, 1995.
17. Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D., Hösch, S., and Hayes, D. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol., 15: 2518-2525, 1997.